ProMetic Life Sciences (PFSCF) Stock Price, News & Analysis

Company Overview

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

Key Stats

• Today's Range: $5.47 to $5.47
• 50-Day Range: $5.47 to $5.47
• 52-Week Range: $5.47 to $352.00
• Volume: N/A
• Average Volume: 279 shs
• Market Capitalization: $127.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PFSCF Stock Analysis - Frequently Asked Questions

How have PFSCF shares performed this year?

ProMetic Life Sciences' stock was trading at $5.4670 at the beginning of 2025. Since then, PFSCF shares have increased by 0.0% and is now trading at $5.4670.
View the best growth stocks for 2025 here.

How do I buy shares of ProMetic Life Sciences?

Shares of PFSCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:PFSCF
• Previous Symbol: NASDAQ:PFSCF
• CIK: N/A
• Web: www.prometic.com
• Phone: 1-450-781-0115
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$150.73 million
• Net Margins: -894.02%
• Pretax Margin: N/A
• Return on Equity: -3,350.55%
• Return on Assets: -67.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.95
• Quick Ratio: 0.71

Sales & Book Value

• Annual Sales: $36.55 million
• Price / Sales: 3.49
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($67.63) per share
• Price / Book: -0.08

Miscellaneous

• Outstanding Shares: 23,313,000
• Free Float: N/A
• Market Cap: $127.45 million
• Optionable: Not Optionable
• Beta: 2.46